Post Blogs, Photos, Youtube, Vimeo Videos, Topics, Events, Groups.
+ Larger Font | - Smaller Font
Share

Welcome to Robins Social Network

Be part of the community and join us today!

Human Microbiome Market - Emerging Trends & Impact of COVID19 on Global Growth

Overview of This Study:

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global Human Microbiome Market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The human microbiome market's size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Projected Surge in Revenue Generation:

The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029.

Data Triangulation:

After arriving at the overall market size-using the market size estimation processes explained above-the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides of the human microbiome market.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Major Growth Influencing Factors:

Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.

Challenge: Government regulations:

The FDA has not approved any probiotics as a live biotherapeutic product (a biological product other than a vaccine that contains live organisms used to prevent or treat a disease or condition in humans). However, there are FDA-regulated foods, including dietary supplements, containing probiotics that are legally available, though these products cannot lawfully be marketed to cure, mitigate, treat, or prevent any diseases.

Probiotic supplements are being aggressively marketed in retail stores and over the Internet. Although no probiotic has been approved for therapeutic purposes by the FDA as of now, some are undergoing clinical trials and may soon be marketed as biologics or other drugs. The current FDA regulatory requirements are not customized for probiotics.

Opportunity: Increasing collaborations between public-private organizations

With several small innovative players operating in the market, there are various high-growth opportunities for key stakeholders to buy out companies so as to study microbiomes in the hope of identifying new drugs and drug targets for various indications, such as obesity, liver disorders, diabetes, and metabolic disorders. Many market leaders are focusing on strategic collaborations and partnerships to increase their product pipelines with well-organized research and development techniques. In the last two years, there have been several collaborations and partnerships involving major companies.

Impact of Covid-19 on Human Microbiome Market

The COVID-19 pandemic has created massive disruptions to clinical trial research across the world. As in other aspects of life, the virus has severely affected the ability to conduct trials in safe and effective ways. This is especially true when considering that trials often deal with vulnerable populations who are most at risk from exposure to COVID-19. Seres Therapeutics’ SER-287 development activity was adversely impacted by the COVID-19 pandemic and by multiple clinical sites halting non-essential procedures, including endoscopies. Similarly, COVID-19 has adversely impacted and could continue to adversely impact the businesses of other companies, including their preclinical studies and clinical trials of microbiome-based therapeutics and diagnostic products.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

The Asia Pacific region is the fastest-growing region of human microbiome research spending market from 2023 to 2029.

Based on region, the global human microbiome research spending market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global human microbiome research spending market in 2021. In 2021, the Asia Pacific region is estimated to grow at the highest CAGR in the human microbiome research spending from 2023-2029.  Factors such as increasing focus on microbiome research and initiatives taken by public and private organizations to increase awareness regarding microbiome therapeutics, are driving the growth of the human microbiome market in the Asia Pacific (APAC) region.

Global Leading Companies:

The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).


on September 6 at 5:49

Comments (0)



Become a member and experience a unique opportunity to post blogs, photos, Youtube Vimeo videos, topics, events, and create groups on Robin's Social Networking Site. Use Robin's Social to sell products, services and market your business when posting blogs.

By registering and posting content, you agree to the terms listed at... Posting Terms and Conditions. Enjoy!

© 2022 Content By Members. All Rights Reserved.